Skip to main content
Biophytis S.A. logo

Biophytis S.A. — Investor Relations & Filings

Ticker · ALBPS ISIN · FR001400OLP5 LEI · 9695008GIE061NBGU106 PA Professional, scientific and technical activities
Open in API
Filings indexed 546 across all filing types
Latest filing 2025-09-03 Regulatory Filings
Country FR France
Listing PA ALBPS

About Biophytis S.A.

https://www.biophytis.com/en/

Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.

Recent filings

Filing Released Lang Actions
Biophytis obtains EMA authorization to launch its Phase 2 clinical trial in obesity
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Biophytis has received EMA authorization to launch a Phase 2 clinical trial. It details the regulatory milestone, the nature of the trial, and provides company contact information. Since it does not fit into specific financial reporting categories like 10-K, IR, or ER, and is a general corporate announcement regarding operational/regulatory progress, it is classified as a Regulatory Filing (RNS).
2025-09-03 English
Biophytis dévoile sa stratégie pour l’essai clinique de phase 2 dans l’obésité avec BIO101 en Europe et au Brésil
Regulatory Filings Classification · 95% confidence The document is a press release issued by Biophytis SA announcing a strategic update regarding a Phase 2 clinical trial for their drug candidate BIO101. It details the trial design, strategic rationale, and future milestones. It does not constitute a full financial report, a regulatory filing, or a transcript, but rather a corporate announcement of operational progress. In the context of financial reporting, such press releases regarding clinical trial updates are classified as Regulatory Filings (RNS) as they serve as general corporate announcements.
2025-09-01 French
Biophytis unveils Phase 2 Obesity Trial Strategy with BIO101 in Europe and Brazil
Regulatory Filings Classification · 95% confidence The document is a press release issued by Biophytis announcing a new clinical trial strategy (Phase 2 OBA trial for BIO101). It details the clinical trial design, strategic rationale, and business opportunities. It does not constitute a formal financial report, a transcript, or a regulatory filing of a specific form type. As it is a corporate announcement regarding business operations and clinical development, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2025-09-01 English
Biophytis obtient l’autorisation de l’EMA et des autorités belges pour démarrer son essai clinique de phase 3 dans la sarcopénie
Regulatory Filings Classification · 95% confidence The document is a press release from Biophytis SA announcing the receipt of regulatory authorization from the EMA and Belgian authorities to commence a Phase 3 clinical trial for sarcopenia. It details the scientific and ethical approvals obtained. As this is a general regulatory announcement regarding company operations and clinical trial progress that does not fit into specific financial reporting categories like 10-K, IR, or ER, it is classified as a Regulatory Filing (RNS).
2025-08-28 French
Biophytis Receives EMA and Belgian Regulatory Approval to Initiate Phase 3 Sarcopenia Clinical Trial
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Biophytis has received regulatory approval from the EMA and Belgian authorities to initiate a Phase 3 clinical trial. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general corporate regulatory announcement regarding clinical trial status, it falls under the 'Regulatory Filings' (RNS) category.
2025-08-28 English
Biophytis sécurise une ligne de financement obligataire non dilutive jusqu’à 1 M€
Capital/Financing Update Classification · 100% confidence The document is a press release from Biophytis SA announcing the securing of a new bond financing line (up to 1 million euros) with Hexagon Capital Fund. It details the terms of the financing, including interest rates, maturity, and potential dilution impact on shareholders. This falls under the category of company fundraising and financing activities.
2025-08-05 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.